{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/036/SRR10601436/SRR10601436.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/039/SRR10601439/SRR10601439.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/035/SRR10601435/SRR10601435.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/032/SRR10601432/SRR10601432.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/031/SRR10601431/SRR10601431.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/033/SRR10601433/SRR10601433.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/034/SRR10601434/SRR10601434.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/030/SRR10601430/SRR10601430.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/040/SRR10601440/SRR10601440.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/038/SRR10601438/SRR10601438.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR106/037/SRR10601437/SRR10601437.fastq.gz"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Department of Data Science, Dana-Farber Cancer Institute"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA593996"],"scientific_name":["Homo sapiens"],"long_description":["von Hippel-Lindau (VHL) is a critical tumor suppres- sor in clear cell renal cell carcinomas (ccRCCs). It is important to identify additional therapeutic targets in ccRCC downstream of VHL loss besides hypox- ia-inducible factor 2a (HIF2a). By performing a genome-wide screen, we identified Scm-like with four malignant brain tumor domains 1 (SFMBT1) as a candidate pVHL target. SFMBT1 was considered to be a transcriptional repressor but its role in cancer remains unclear. ccRCC patients with VHL loss-of- function mutations displayed elevated SFMBT1 pro- tein levels. SFMBT1 hydroxylation on Proline residue 651 by EglN1 mediated its ubiquitination and degra- dation governed by pVHL. Depletion of SFMBT1 abolished ccRCC cell proliferation in vitro and in- hibited orthotopic tumor growth in vivo. Integrated analyses of ChIP-seq, RNA-seq, and patient prog- nosis identified sphingosine kinase 1 (SPHK1) as a key SFMBT1 target gene contributing to its onco- genic phenotype. Therefore, the pVHL-SFMBT1- SPHK1 axis serves as a potential therapeutic avenue for ccRCC Overall design: ChIP-seq for SFMBT1 and input control. RNA-seq for two independent siRNA against SFMBT1, as well as scrambled control, each performed in triplicate."],"tag":["xref:PubMed:32023483"],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss","description":"Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss","dates":{"last_updated":"2025-09-24","first_public":"2020-02-06"},"accession":"PRJNA593996","cross_references":{"GEO":["GSE141577"],"taxon":["9606"],"PubMed":["32023483"]}}